Literature DB >> 11895762

Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease.

Tomasz Szczepański1, Marja J Willemse, Bas Brinkhof, Elisabeth R van Wering, Mirjam van der Burg, Jacques J M van Dongen.   

Abstract

Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements are excellent patient-specific polymerase chain reaction (PCR) targets for detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL), but they might be unstable during the disease course. Therefore, we performed detailed molecular studies in 96 childhood precursor-B-ALL at diagnosis and at relapse (n = 91) or at presumably secondary acute myeloid leukemia (n = 5). Clonal Ig and TCR targets for MRD detection were identified in 94 patients, with 71% of these targets being preserved at relapse. The best stability was found for IGK-Kde rearrangements (90%), followed by TCRG (75%), IGH (64%), and incomplete TCRD rearrangements (63%). Combined Southern blot and PCR data for IGH, IGK-Kde, and TCRD genes showed significant differences in stability at relapse between monoclonal and oligoclonal rearrangements: 89% versus 40%, respectively. In 38% of patients all MRD-PCR targets were preserved at relapse, and in 40% most of the targets (> or = 50%) were preserved. In 22% of patients most targets (10 cases) or all targets (10 cases) were lost at relapse. The latter 10 cases included 4 patients with secondary acute myeloid leukemia with germline Ig/TCR genes. In 5 other patients additional analyses proved the clonal relationship between both disease stages. Finally, in 1 patient all Ig/TCR gene rearrangements were completely different between diagnosis and relapse, which is suggestive of secondary ALL. Based on the presented data, we propose stepwise strategies for selection of stable PCR targets for MRD monitoring, which should enable successful detection of relapse in most (95%) of childhood precursor-B-ALL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895762     DOI: 10.1182/blood.v99.7.2315

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

Review 1.  The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies.

Authors:  Anna Gazzola; Claudia Mannu; Maura Rossi; Maria Antonella Laginestra; Maria Rosaria Sapienza; Fabio Fuligni; Maryam Etebari; Federica Melle; Elena Sabattini; Claudio Agostinelli; Francesco Bacci; Carlo Alberto Sagramoso Sacchetti; Stefano Aldo Pileri; Pier Paolo Piccaluga
Journal:  Ther Adv Hematol       Date:  2014-04

2.  Consensus JH gene probes with conjugated 3'-minor groove binder for monitoring minimal residual disease in acute lymphoblastic leukemia.

Authors:  Michihiro Uchiyama; Chihaya Maesawa; Akiko Yashima-Abo; Mitsu Tarusawa; Mikiya Endo; Waka Sugawara; Shoichi Chida; Shima Onodera; Yasuhiko Tsukushi; Yoji Ishida; Shigeru Tsuchiya; Tomoyuki Masuda
Journal:  J Mol Diagn       Date:  2005-02       Impact factor: 5.568

3.  Immunoglobulin and T-cell receptor gene rearrangements: minding your B's and T's in assessing lineage and clonality in neoplastic lymphoproliferative disorders.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

Review 4.  Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies.

Authors:  Jacques J M van Dongen; Vincent H J van der Velden; Monika Brüggemann; Alberto Orfao
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

5.  Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.

Authors:  Klaus Wethmar; Svenja Matern; Eva Eßeling; Linus Angenendt; Heike Pfeifer; Monika Brüggemann; Patrick Stelmach; Simon Call; Jörn C Albring; Jan-Henrik Mikesch; Christian Reicherts; Christoph Groth; Christoph Schliemann; Wolfgang E Berdel; Georg Lenz; Matthias Stelljes
Journal:  Bone Marrow Transplant       Date:  2020-01-30       Impact factor: 5.483

6.  Evaluation diagnostic usefulness of immunoglobulin light chains (Igκ, Igλ) and incomplete IGH D-J clonal gene rearrangements in patients with B-cell non-Hodgkin lymphomas using BIOMED-2 protocol.

Authors:  S Ghorbian; I Jahanzad; G R Javadi; E Sakhinia
Journal:  Clin Transl Oncol       Date:  2014-05-27       Impact factor: 3.405

7.  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.

Authors:  Michael J Borowitz; Meenakshi Devidas; Stephen P Hunger; W Paul Bowman; Andrew J Carroll; William L Carroll; Stephen Linda; Paul L Martin; D Jeanette Pullen; David Viswanatha; Cheryl L Willman; Naomi Winick; Bruce M Camitta
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

8.  Flow cytometry and polymerase chain reaction-based analyses of minimal residual disease in chronic lymphocytic leukemia.

Authors:  Sabrina Uhrmacher; Felix Erdfelder; Karl-Anton Kreuzer
Journal:  Adv Hematol       Date:  2010-09-20

9.  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Authors:  Malek Faham; Jianbiao Zheng; Martin Moorhead; Victoria E H Carlton; Patricia Stow; Elaine Coustan-Smith; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

10.  Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.

Authors:  Małgorzata Dawidowska; Justyna Jółkowska; Tomasz Szczepański; Katarzyna Derwich; Jacek Wachowiak; Michał Witt
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-12-01       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.